Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib added to thalidomide + dexamethasone after ASCT for multiple myeloma
ACTRN12616000772448Phase 3Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Jan 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of ixazomib, thalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Progression-free survival. Started Jan 2017; status: completed.
02
Drugs
ixazomibthalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12616000772448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000772448.